Apc mice: Models, modifiers and mutants
Section snippets
Colorectal cancer and APC
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world and is currently the third most common form of cancer. Mutations in the Adenomatous polyposis coli (APC) gene are responsible for the familial adenomatous polyposis (FAP) syndrome, and are an early causative event in sporadic cancer development [45]. APC is a large multidomain protein (2843 amino acids) that functions to down-regulate the Wnt signalling pathway by binding to and promoting the
The Min mouse
The multiple intestinal neoplasia (Min) mouse was identified following random mutagenesis with ethylnitrosourea [42]. It was subsequently established that a truncating mutation at codon 850 of Apc was responsible for the phenotype, which resembles that of human FAP [74]. Mice carrying a heterozygous mutation, ApcMin/+, develop approximately 30 small intestinal polyps (both pedunculated polyps and flat adenomas) when on the C57BL/6 background; polyps only occasionally progress to invasive
Modifiers of the Min phenotype
Distinct human kindreds with identical mutant APC alleles display diverse phenotypes, including colonic polyp burden. Such diversity is often thought to be due to environment, particularly diet, or genetic modifiers: genes that alter disease severity by interacting, directly or indirectly, with the primary genetic mutation causing the disease. Interestingly, this scenario is repeated in the ApcMin/+ mouse, which under normal laboratory conditions is considered to be genetically and
Apc mutations and the mouse
Many genetically engineered mouse (GEM) strains have been generated in an attempt to more accurately model the mutations common in FAP kindreds and sporadic CRCs. These models, as for the Min model, require loss of the wild-type Apc allele in order for tumorigenesis to take place. While onset, severity and location of tumors is Apc mutation-dependent, the tumor histology of the various Apc mutant mice is similar [9]. Pertinent examples of such GEM are outlined in Table 2 and a schematic
Apc compound mutants
Despite the wealth of information that mouse models of Apc deficiency have provided about the in vivo biology of this protein, there are several critical drawbacks in relating these models to human intestinal neoplasia. For example, in Apc mouse models, polyp formation is favored in the small intestine, in contrast to human disease, which occurs predominantly in the colon. There is still no adequate explanation for this. Crucially, there is little or no invasion of tumors arising in Apc mouse
Apc mouse models provide insight into the role of Wnt pathway components in CRC
The pathological changes associated with Apc deficiency include increases in crypt size, cell proliferation and apoptosis. In addition, the cells in Apc-deficient crypts show reduced crypt to villus migration and differentiation [2]. There is considerable interest in understanding the molecular pathways associated with these phenotypes, and several investigations have been aimed at elucidating the additional genes involved. In contrast to what has been previously thought, studies using an
Genomic in stability
There are two types of genomic instability known to play a role in human tumorigenesis: chromosomal instability resulting in losses and/or gains of chromosomal regions and microsatellite instability, characteristic of mismatch repair (MMR) deficiency. Both types of instability have been shown to enhance intestinal neoplasia in Apc mouse models.
LOH of the wild-type Apc allele is one of the initiating events of tumor formation in Apc mouse models of intestinal neoplasia, and mitotic recombination
Epigenetic modifiers
Aberrant epigenetic state is a hallmark of cancer, due to dual roles in genome stability and gene expression. Human cancers are known to be associated with both hypo- and hyper-methylation of genomic DNA [83]. Deficiency of DNA methyltransferases and methyl-binding proteins suppress intestinal polyp formation in ApcMin/+ mice while promoting tumorigenesis in other tissues [38], [59], [84]. Notably, while loss of the maintenance DNA methyltransferase, Dnmt1, was implicated in promoting colonic
Prostaglandin biosynthesis
Prostaglandins are thought to contribute to tumorigenesis through their role in cell proliferation, apoptosis, differentiation and angiogenesis. Apc mouse models have provided considerable insight into the importance of these metabolites in vivo, revealing that many of the genes involved in their production have dramatic effects on tumor multiplicity and size. Disruption of the genes encoding Cox-1 and Cox-2 (Ptgs1 and Ptgs2), led to an approximately 80% reduction of polyp numbers and decrease
Compound mice giving rise to adenocarcinoma
Due to the general lack of invasive tumors in Apc mouse models, studies have focused particular attention on the influence of genes known to be important in the adenoma–carcinoma transition in efforts to recapitulate invasive disease in the mouse. The signal transducer Kras is found mutated in 40–50% of all human CRCs [61], but not in polyps from Apc mouse models [47], [70]. Apc-deficient mice (Apc580D) carrying an oncogenic Kras allele showed that 17% of tumors developed into aggressive
Reference (84)
- et al.
Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis
Cell
(1995) - et al.
Pathology of mouse models of intestinal cancer: consensus report and recommendations
Gastroenterology
(2003) - et al.
Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers
Lab. Invest.
(2004) - et al.
Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse
Cell
(1993) - et al.
Meiotic pachytene arrest in MLH1-deficient mice
Cell
(1996) - et al.
Non-traditional roles for the Adenomatous polyposis coli (APC) tumor suppressor protein
Gene
(2005) - et al.
The secretory phospholipase A2 gene is a candidate for the Mom1 locus a major modifier of ApcMin-induced intestinal neoplasia
Cell
(1995) - et al.
Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
Cell
(1996) - et al.
Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice
Cancer Cell
(2002) - et al.
Spontaneous aberrant crypt foci in Apc1638N mice with a mutant Apc allele
Am. J. Pathol.
(2003)
Cyclin D1 is not an immediate target of betacatenin following Apc loss in the intestine
J. Biol. Chem.
Apc1638N: a mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts
Gastroenterology
Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes
Cell
Smad4 haploinsufficiency in mouse models for intestinal cancer
Oncogene
Cryptrestricted proliferation and commitment to the paneth cell lineage following Apc loss in the mouse intestine
Development
Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/− compound mutant mice
Nat. Genet.
Enhanced intestinal adenomatous polyp formation in Pms2−/−; Min mice
Cancer Res.
The modifier of Min 2 (Mom2) locus: embryonic lethality of a mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression
Genome Res.
EphB receptor activity suppresses colorectal cancer progression
Nature
Sulindac suppresses tumorigenesis in the Min mouse
Carcinogenesis
APC mutations lead to cytokinetic failures in vitro and tetraploid genotypes in Min mice
J. Cell Biol.
Estrogen receptors alpha and beta are inhibitory modifiers of Apc dependent tumorigenesis in the proximal colon of Min/+ mice
Cancer Res.
Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice
Cancer Res.
The Mom1AKR intestinal tumor resistance region consists of Pla2g2a and a locus distal to D4Mit64
Oncogene
Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc (Min/+) Dnmt1-hypomorphic mice
Cancer Res.
Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice
Cancer Res.
The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression
Cancer Res.
A targeted chain termination mutation in the mouse Apc gene results in multiple intestinal tumors
Proc. Natl. Acad. Sci. USA
Mom1 is a semi-dominant modifier of intestinal adenoma size and multiplicity in Min/+ mice
Genetics
Action of min and mom1 on neoplasia in ectopic intestinal grafts
Cell Growth Differ.
Genetic evaluation of candidate genes for the mom1 modifier of intestinal neoplasia in mice
Genetics
A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity
Nat. Genet.
Genetic basis of variation in adenoma multiplicity in Apcmin/+ mom1s mice
Proc. Natl. Acad. Sci. USA
Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers
Proc. Natl. Acad. Sci. USA
Compound disruption of smad2 accelerates malignant progression of intestinal tumors in Apc knockout mice
Cancer Res.
Mouse model of colonic adenomacarcinoma progression based on somatic Apc inactivation
Cancer Res.
Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice
Mol. Cell Biol.
Modeling metastasis in vivo
Carcinogenesis
Haploinsufficiency of Flap endonuclease (Fen1) leads to rapid tumor progression
Proc. Natl. Acad. Sci. USA
Tumor-associated Apc mutations in Mlh1−/− Apc1638N mice reveal a mutational signature of Mlh1 deficiency
Oncogene
The distinct spectra of tumor-associated Apc mutations in mismatch repair-deficient Apc1638N mice define the roles of MSH3 and MSH6 in DNA repair and intestinal tumorigenesis
Cancer Res.
Adenomatous polyposis coli (APC) is required for normal development of skin and thymus
PLoS Genet.
Cited by (136)
Animal models of cancer-associated cachexia
2019, Animal Models in Cancer Drug DiscoveryDual gene deficient models of Apc<sup>Min/+</sup> mouse in assessing molecular mechanisms of intestinal carcinogenesis
2018, Biomedicine and Pharmacotherapy
- 1
These authors contributed equally.